CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer

Early Stage Non-small Cell Lung Cancer Clinical Trial

Official title: Clinical Outcome of CT-guided Radioactive Iodine-125 Seeds Implantation for Inoperable Early Stage Non-small Cell Lung Cancer

Status Completed

Clinical Trial Summary

This study observes the efficacy and side effects of CT-guided radioactive iodine-125 seed brachytherapy in inoperable early stage non-small cell lung cancer retrospectively, and analyzes the influence of clinical and dosimetric factors on the outcomes.

Clinical Trial Description

Radioactive Iodine-125 seed brachytherapy is a conventional treatment in Peking University Third Hospital. Radioactive Iodine-125 seed brachytherapy is the implantation of Iodine-125 seed into tumors.The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. This study collects the data of patients with early stage (stage I-II, N0) non-small cell lung cancer who underwent CT-guided radioactive Iodine-125 seed implantation from 2010 to 2018. The investigators evaluate the dose that covers 90% target volume(D90) and other parameters after the implantation. The efficacy and adverse effects were observed. Local control(LC) time and overall survival(OS) time are evaluated. ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Early Stage Non-small Cell Lung Cancer
• Lung Neoplasms

• NCT number: NCT03916367
• Study type: Observational
• Source: Peking University Third Hospital
• Status: Completed
• Start date: December 15, 2010
• Completion date: February 15, 2019